Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009

This article was originally published in The Pink Sheet Daily

Executive Summary

Questions over whether the deal will pass FTC muster demonstrate how jittery industry is becoming following a criminal probe into a Sanofi/Bristol agreement.
Advertisement

Related Content

ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
Shire Specialty Pharmaceuticals President Mike Cola: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Shire Patent Infringement Suit Over Adderall XR Triggers 30-Month Stay
Shire Expects Next-Generation Adderall XR Approval Following DEA Scheduling
Barr Takes Over Adderall IR From Shire
Cephalon Provigil Generics Settlements Under FTC Investigation
Shire’s New ADHD Drug Coming Into Focus
Bristol/Sanofi's Plavix Settlement Faces Justice Department Criminal Investigation
Shire Settles Adderall XR Patent Case With Impax, But Remains At Impasse With Barr
Shire Settles Adderall XR Patent Case With Impax, But Remains At Impasse With Barr

Topics

Advertisement
UsernamePublicRestriction

Register

PS064678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel